MedTrace Logo

The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination

NCT01866566 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2013-06-26

No results posted yet for this study

Summary

Through evaluating the immunogenicity and safety for Varicella vaccine two doses immune procedure we could supply scientific and practical evidence for this two doses immune procedure promotion and management.

Conditions

  • Varicella

Interventions

BIOLOGICAL

HBV-3

Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month

BIOLOGICAL

HBV-6

Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month

BIOLOGICAL

varicella-3

Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month

BIOLOGICAL

varicella-6

Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month

Sponsors & Collaborators

  • Beijing Center for Disease Control and Prevention

    lead OTHER_GOV

Principal Investigators

  • Nianmin Shi · Beijing Chaoyang District Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-01-31
Completion
2016-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01866566 on ClinicalTrials.gov